Briacell Therapeutics Corp Asset Resilience Ratio
Briacell Therapeutics Corp asset resilience ratio. Briacell Therapeutics Corp (BCTX) has an Asset Resilience Ratio of 58.82% as of April 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Briacell Therapeutics Corp liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Briacell Therapeutics Corp (2011–2025)
Asset resilience ratio of Briacell Therapeutics Corp from 2011 to 2025. This chart shows how Briacell Therapeutics Corp's Asset Resilience Ratio has changed over time. Read how much debt does Briacell Therapeutics Corp carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Briacell Therapeutics Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Briacell Therapeutics Corp asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.92 Million | 58.82% |
| Total Liquid Assets | $15.92 Million | 58.82% |
Asset Resilience Insights
- Very High Liquidity: Briacell Therapeutics Corp maintains exceptional liquid asset reserves at 58.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Briacell Therapeutics Corp Industry Peers by Asset Resilience Ratio
Compare Briacell Therapeutics Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Briacell Therapeutics Corp Asset Resilience Ratio by Year (2011–2025)
Briacell Therapeutics Corp asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Briacell Therapeutics Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-07-31 | 34.05% | $10.14 Million | $29.77 Million | +34.05pp |
| 2024-07-31 | 0.00% | $175.00 | $8.15 Million | -45.04pp |
| 2018-07-31 | 45.04% | $1.03 Million | $2.28 Million | +8.27pp |
| 2017-07-31 | 36.78% | $601.76K | $1.64 Million | -29.92pp |
| 2015-07-31 | 66.70% | $851.24K | $1.28 Million | +61.34pp |
| 2013-07-31 | 5.36% | $504.49K | $9.41 Million | -0.11pp |
| 2012-07-31 | 5.48% | $564.98K | $10.32 Million | -3.48pp |
| 2011-07-31 | 8.96% | $1.11 Million | $12.35 Million | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more